Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00547612|
Recruitment Status : Completed
First Posted : October 22, 2007
Last Update Posted : March 16, 2012
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer.
PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Other: high performance liquid chromatography Other: pharmacological study Radiation: [18F]-labeled substance P antagonist receptor quantifier||Phase 1|
- Determine whether [18F]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||33 participants|
|Official Title:||Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
- Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00547612
|United States, Maryland|
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office|
|Bethesda, Maryland, United States, 20892-1182|
|Study Chair:||Richard E. Royal, MD, FACS||NCI - Surgery Branch|